Prosecution Insights
Last updated: April 19, 2026

Cytomx Therapeutics Inc.

3 pending office actions

Portfolio Summary

3
Total Pending OAs
2
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18534263 MATRIPTASE AND U-PLASMINOGEN ACTIVATOR SUBSTRATES AND OTHER CLEAVABLE MOIETIES AND METHODS OF USE THEREOF NIEBAUER, RONALD T 1658 Final Rejection Dec 08, 2023
17790835 AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF MARTIN, KEVIN STEPHEN 1624 Final Rejection Jul 05, 2022
17230240 MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME BRISTOL, LYNN ANNE 1643 Non-Final OA Apr 14, 2021

Managing Cytomx Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month